Advanced Medical Solutions Group (LSE:AMS) Cash-to-Debt : 6.58 (As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

What is Advanced Medical Solutions Group Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Advanced Medical Solutions Group's cash to debt ratio for the quarter that ended in Dec. 2023 was 6.58.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Advanced Medical Solutions Group could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Advanced Medical Solutions Group's Cash-to-Debt or its related term are showing as below:

LSE:AMS' s Cash-to-Debt Range Over the Past 10 Years
Min: 4.84 Med: 7.51 Max: 34201
Current: 6.58

During the past 13 years, Advanced Medical Solutions Group's highest Cash to Debt Ratio was 34201.00. The lowest was 4.84. And the median was 7.51.

LSE:AMS's Cash-to-Debt is ranked better than
68.41% of 861 companies
in the Medical Devices & Instruments industry
Industry Median: 1.87 vs LSE:AMS: 6.58

Advanced Medical Solutions Group Cash-to-Debt Historical Data

The historical data trend for Advanced Medical Solutions Group's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Advanced Medical Solutions Group Cash-to-Debt Chart

Advanced Medical Solutions Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

6.25

4.84

7.40

8.44

6.58

Advanced Medical Solutions Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															7.40	7.99	8.44	7.53	6.58

Competitive Comparison of Advanced Medical Solutions Group's Cash-to-Debt

For the Medical Instruments & Supplies subindustry, Advanced Medical Solutions Group's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Advanced Medical Solutions Group's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Advanced Medical Solutions Group's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Advanced Medical Solutions Group's Cash-to-Debt falls into.

Advanced Medical Solutions Group Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Advanced Medical Solutions Group's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	60.16	/	(1.164	+	7.973)
	=	6.58

Advanced Medical Solutions Group's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	60.16	/	(1.164	+	7.973)
	=	6.58

Advanced Medical Solutions Group (LSE:AMS) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Advanced Medical Solutions Group Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Advanced Medical Solutions Group's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Advanced Medical Solutions Group (LSE:AMS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Advanced Medical Solutions Group PLC (LSE:AMS) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

AMS.GB:UK AQA:Germany

Address

Premier Park, 33 Road One, Winsford Industrial Estate, Winsford, Cheshire, GBR, CW7 3RT

Website

https://www.admedsol.com

U.K.-based Advanced Medical Solutions was founded in 1991 to design, develop, and manufacture advanced wound-care products for other healthcare manufacturers. AMS' key branded products include the ActivHeal franchise of hydrogel, hydrocolloid, foam, and alginate wound dressings. The firm also manufactures and markets a suite of branded products in surgical use, including the LiquiBand franchise for tissue adhesion and the Resorba line of sutures and collagen-based products for tissue repair. The firm derives approximately 60% of total revenue from branded products, with nonbranded contributing 40%.